Kura Oncology, Inc. (NASDAQ:KURA) SVP Sells $38,948.63 in Stock

Kura Oncology, Inc. (NASDAQ:KURA) SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Kura Oncology Stock Performance

NASDAQ KURA opened at $8.03 on Friday. The firm has a market cap of $624.41 million, a price-to-earnings ratio of -3.40 and a beta of 0.81. The company has a 50 day moving average of $9.02 and a 200-day moving average of $15.58. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology, Inc. has a 1-year low of $6.98 and a 1-year high of $24.17.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.01. During the same quarter last year, the business posted ($0.50) earnings per share. On average, equities analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Institutional Trading of Kura Oncology

Hedge funds and other institutional investors have recently modified their holdings of the stock. nVerses Capital LLC acquired a new stake in shares of Kura Oncology in the third quarter valued at approximately $25,000. China Universal Asset Management Co. Ltd. boosted its stake in Kura Oncology by 11.9% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company’s stock valued at $144,000 after acquiring an additional 1,750 shares during the last quarter. Point72 DIFC Ltd bought a new position in Kura Oncology in the third quarter valued at approximately $146,000. Quarry LP bought a new position in Kura Oncology in the second quarter valued at approximately $196,000. Finally, Erste Asset Management GmbH bought a new position in Kura Oncology in the third quarter valued at approximately $215,000.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on KURA. StockNews.com cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Wednesday, November 20th. HC Wainwright increased their target price on shares of Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, November 21st. Bank of America reduced their target price on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research note on Friday, November 22nd. Jefferies Financial Group reduced their target price on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research note on Thursday, November 21st. Finally, TD Cowen reiterated a “buy” rating on shares of Kura Oncology in a research note on Thursday, November 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $27.38.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.